Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Cutler

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administrationD Pajkrt, L Camoglio, M C Tiel-van Buul, et al.
Cancer Research|April 15, 2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei, C Erlichman, J N Davis, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administrationD Pajkrt, L Camoglio, M C Tiel-van Buul, et al.
Cancer Research|April 15, 2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei, C Erlichman, J N Davis, et al.
Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.
Pageof 6